284 related articles for article (PubMed ID: 31179423)
1. Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia.
Weng J; Zhang Y; Li H; Shen Y; Yu W
Gen Psychiatr; 2019; 32(1):e100026. PubMed ID: 31179423
[TBL] [Abstract][Full Text] [Related]
2. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
Plesnicar BK; Zalar B; Breskvar K; Dolzan V
J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of depression and its relationship with other clinical characteristics in a sample of patients with stable schizophrenia.
Majadas S; Olivares J; Galan J; Diez T
Compr Psychiatry; 2012 Feb; 53(2):145-51. PubMed ID: 21621754
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics.
De Nayer A; Windhager E; Irmansyah ; Larmo I; Lindenbauer B; Rittmannsberger H; Platz T; Jones A; Whiteford J; Altman C
Int J Psychiatry Clin Pract; 2003; 7(1):59-66. PubMed ID: 24937244
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
[TBL] [Abstract][Full Text] [Related]
7. Clinical Usefulness of Amisulpride Add-on Therapy in Schizophrenia Patients without Treatment Response to Second-generation Antipsychotics.
Kang SG; Cho SE; Na KS; Pae CU; Cho SJ
Clin Psychopharmacol Neurosci; 2021 Feb; 19(1):117-124. PubMed ID: 33508795
[TBL] [Abstract][Full Text] [Related]
8. Relating Spontaneously Reported Extrapyramidal Adverse Events to Movement Disorder Rating Scales.
Widschwendter CG; Karayal ON; Kolluri S; Vanderburg D; Kemmler G; Fleischhacker WW
Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26116494
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
[TBL] [Abstract][Full Text] [Related]
10. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients.
Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK
Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of low-dose D
Weng JJ; Wang LH; Zhu H; Xu WR; Wei YM; Wang ZY; Yu WJ; Li HF
Neuropsychiatr Dis Treat; 2019; 15():2195-2203. PubMed ID: 31496702
[TBL] [Abstract][Full Text] [Related]
12. Validity and Reliability Study of Turkish Version of Clinical Assessment Interview for Negative Symptoms (CAINS).
Vayisoğlu S; Karahan S; Gürel ŞC; Yağcioğlu AEA
Noro Psikiyatr Ars; 2024; 61(1):59-65. PubMed ID: 38496217
[TBL] [Abstract][Full Text] [Related]
13. [Switching patients with schizophrenia to ziprasidone from conventional or other atypical antipsychotics].
Bartkó G; Trixler M; Bitter I; Degrell I; Füredi J; Faludi G;
Neuropsychopharmacol Hung; 2006 Dec; 8(4):201-9. PubMed ID: 17211055
[TBL] [Abstract][Full Text] [Related]
14. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment.
Gebhardt S; Härtling F; Hanke M; Mittendorf M; Theisen FM; Wolf-Ostermann K; Grant P; Martin M; Fleischhaker C; Schulz E; Remschmidt H
Eur Child Adolesc Psychiatry; 2006 Oct; 15(7):371-82. PubMed ID: 16648965
[TBL] [Abstract][Full Text] [Related]
16. Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.
Sarró S; Dueñas RM; Ramírez N; Arranz B; Martínez R; Sánchez JM; González JM; Saló L; Miralles L; San L
Schizophr Res; 2004 Jun; 68(2-3):349-56. PubMed ID: 15099616
[TBL] [Abstract][Full Text] [Related]
17. The Greek version of the calgary depression scale for schizophrenia.
Kontaxakis VP; Havaki-Kontaxaki BJ; Margariti MM; Stamouli SS; Kollias CT; Angelopoulos EK; Christodoulou GN
Psychiatry Res; 2000 May; 94(2):163-71. PubMed ID: 10808041
[TBL] [Abstract][Full Text] [Related]
18. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
[TBL] [Abstract][Full Text] [Related]
20. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
Ivanov SV; Smulevich AB; Voronova EI; Yakhin KK; Beybalaeva TZ; Katok AA
Front Psychiatry; 2021; 12():770592. PubMed ID: 35140638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
